Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms

Integrative Cancer Therapies

Volumn 8, Issue 4, 2009, Pages 387-397

  Hrushesky, William J M ^a,b   Grutsch, James ^c   Wood, Patricia ^a,b   Yang, Xiaoming ^a   Oh, Eun Young ^a   Ansell, Christine ^a   Kidder, Stephanie ^a   Ferrans, Carol ^d   Quiton, Dinah Faith T ^a,b   Reynolds, Justin ^a   Du Quiton, Jovelyn ^a,b   Levin, Robert ^c   Lis, Christopher ^c   Braun, Donald ^c  

^a WJB Dorn VA Medical Center   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c CANCER TREATMENT CENTERS OF AMERICA   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anxiety; Circadian rhythm; Depression; Fatigue; Lung cancer; Quality of life; Sleep

Indexed keywords

MELATONIN; PER1 PROTEIN; PER2 PROTEIN;

ACTIMETRY; ANXIETY; BONE MARROW; BREAST CANCER; CANCER FATIGUE; CANCER GROWTH; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CIRCADIAN RHYTHM; COLON CANCER; DEPRESSION; DNA REPAIR; FUNCTIONAL STATUS; GENE MUTATION; HUMAN; INTESTINE; LUNG CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN; SLEEP; STEM CELL; SYMPTOM; TUMOR SUPPRESSOR GENE;

ANIMALS; BEHAVIOR THERAPY; CHRONOBIOLOGY DISORDERS; CHRONOTHERAPY; CIRCADIAN RHYTHM; HUMANS; LIFE STYLE; MELATONIN; NEOPLASMS; QUALITY OF LIFE;

EID: 77949385561     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735409352086     Document Type: Review

References (77)

1. Halberg F, Gehrke CW, Zinneman HH, et al. Circadian rhythms in polyamine excretion by rats bearing an immunocytoma. Chronobiologia. 1976;3:309-322.
2. Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet. 2008;9: 764-775.
3. Hoyt D, Schatten K. The Role of the Sun in Climate Change. New York, NY: Oxford University Press; 1997.
4. Scheving LLE, Tsai TH, Sothern RB, Hrushesky WJ. Circadian susceptibility: resistance cycles to radiation and their manipulability by methylene blue. Pharmacol Ther. 1988;39: 397-402.
5. Haus E, Halbeg F, Loken MK. Circadian susceptibilityresistance cycle of bone marrow cells to whole body x-irradiation in BALB/c mice. In: Scheving LE, Halberg F, Pauly JE, eds. Chronobiology: Proceedings of the International Society for the Study of Biological Rhythms. Stuttgart, Germany: Georg Thieme; 1974:115-122.
6. Tsai T, Burns E, Scheving LE, Circadian differences in anticancer immunity induced by BCG. Anat Rec. 1974;178:478.
7. Kang TH, Reardon JT, Kemp M, Sancar A. Circadian oscillation of nucleotide excision repair in mammalian brain. Proc Natl Acad Sci U S A. 2009;106:2864-2867.
8. Hrushesky WJM, Lannin D, Haus E. Evidence for an ontogenetic basis for circadian coordination of cancer cell proliferation. J Natl Cancer Inst. 1998;90:1480-1484.
9. Granda TG, Liu XH, Smaaland R, et al. Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB J. 2004;19:304-306.
10. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003;302:255-259.
11. Hrushesky WJM, Langer R, Theeuwes F, eds. Temporal control of drug delivery. Ann N Y Acad Sci. 1991;618:102-115.
12. Scheving LE. Mitotic activity in the human epidermis. Anat Rec. 1959;135:7-19.
13. Scheving LE, Burns ER, Pauly JE, Tsai TH. Circadian variation in cell division of the mouse alimentary tract, bone marrow and corneal epithelium. Anat Rec. 1978;191:479-486.
14. Buchi KN, Moore JG, Hrushesky WJ, Sothern RB, Rubin NH. Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology. 1991;101:410-415.
15. Wood PA, Du-Quiton J, You S, Hrushesky WJ. Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther. 2006;5:2023-2033.
16. Wood P, Sanchez de la Pena S, Hrushesky WJM. Evidence for circadian dependency of recombinant human erythropoietin (rhEPO) response in the mouse. Ann N Y Acad Sci. 1991;618:610-612.
17. Wood PA, Hrushesky WJ, Klevecz P, et al. Efficacy of chronic erythropoietin is dependent upon the time of day of its administration. Exp Hematol. 1994;22:707.
18. Hrushesky WJ. Circadian timing of cancer chemotherapy. Science. 1985;228:73-75.
19. Lévi F, Zidani R, Misset J. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997;350:681-686.
20. Lucas D, Battista M, Shi PA, Isola L, Frenette PS. Mobilized hematopoietic stem cell yield depends on species-specific circadian timing. Cell Stem Cell. 2008;3:364-366.
21. Abrahamsen J, Smaaland R, Sothern RB, Laerum OD. Variation in cell yield and proliferative activity of positive selected human CD34+ bone marrow cells along circadian time scale. Eur J Haematol. 1998;60:7-15.
22. Haus E, Halberg F, Pauly JE, et al. Increased tolerance of mice to arabinosyl cytosine given on schedule adjusted to circadian system. Science. 1972;177:80-82.
23. Smaaland R, Lote K, Sothern RB, Laerum OD. DNA synthesis and ploidy in non-Hodgkin's lymphomas demonstrate intrapatient variation depending on circadian stage of cell sampling. Cancer Res. 1993;53:3129-3138.
24. Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK, Koeffler HP. Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood. 2005;106:2827-2836.
25. Gery S, Komatsu N, Kawamata N. Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res. 2007;13:1399-1404.
26. Smaaland R, Svardal AM, Lote K, Ueland M, Laerum OD. Glutathione content in human bone marrow and circadian stage relation to DNA synthesis. J Natl Cancer Inst. 1991;83:1092-1098.
27. Bellamy WT, Alberts DS, Dorr RT. Daily variation in nonprotein sulfhydryl levels of human bone marrow. Eur J Cancer Clin Oncol. 1988;24:1759-1762.
28. You S, Wood PA, Xiong Y, Kobayashi M, Du-Quiton J, Hrushesky WJ. Daily coordination of cancer growth and circadian clock gene expression. Breast Cancer Res Treat. 2005;91:47-60.
29. Gorbacheva VY, Kondratov RV, Zhang R, et al. Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/ BMAL1 transactivation complex. Proc Natl Acad Sci U S A. 2005;102:3407-3412.
30. Fu L, Lee C. The circadian clock: pacemaker and tumor suppressor. Nat Rev Cancer. 2003;3:350-361.
31. Filipski E, Delaunay F, King VM, et al. Effects of chronic jet lag on tumor progression in mice. Cancer Res. 2004;64: 7879-7885.
32. Dauchy RT, Sauer LA, Blask DE, Vaughan GM. Light contamination during the dark phase in "photoperiodically controlled" animal rooms: effect on tumor growth and metabolism in rats. Lab Anim Sci. 1997;47:511-518.
33. Filipski E, King VM, Etienne MC, et al. Persistent twentyfour hour changes in liver and bone marrow despite suprachiasmatic nuclei ablation in mice. Am J Physiol Regul Integr Comp Physiol. 2004;287:R844-R851.
34. Wood P, Yang YM, Oh EY, et al. Light at night induced breast cancer growth acceleration depends on melatonin and tumor melatonin MT1 receptor expression. Paper presented at: The Role of Genetic and Gene Expression in Sleep Regulation and Dysregulation; June 20, 2008; New York, NY.
35. Lee C, Weaver D, Reppert S. Direct association between mouse PERIOD and CKIe is critical for a functioning clock. Mol Cell Biol. 2004;24:584-594.
36. Yang X, Wood PA, Oh EY, Du-Quiton J, Ansell CM, Hrushesky WJ. Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat. 2009;117:423-431.
37. Yang X, Wood PA, Ansell CM, et al. The circadian clock gene Per1 suppresses cancer cell proliferation and tumor growth at specific times of day. Chronobiol Int. In press.
38. Burch JB, Hrushesky W. The protective role of melatonin in breast cancer. Breast Dis. 2009;20:240-245.
39. Schernhammer ES, Laden F, Speizer FE, et al. Night-shift ork and risk of colorectal cancer in the Nurses' Health Study. J Natl Cancer Inst. 2003;95:825-828.
40. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2001;93: 1557-1562.
41. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. J Natl Cancer Inst. 2001;93:1563-1568.
42. Schernhammer ES, Berrino F, Krogh V, et al. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2008;100:898-905.
43. Burch JB, Tom J, Zhai Y, Criswell L, Leo E, Ogoussan K. Shiftwork impacts and adaptation among health care workers. Occup Med (Lond). 2009;59:159-166.
44. Krugluger W, Brandstaetter A, Kállay E, et al. Regulation of genes of the circadian clock in human colon cancer: reduced Period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors. Cancer Res. 2007;67: 7917-7922.
45. Wood PA, Yang X, Taber A, et al. Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res. 2008;6: 1786-1793.
46. Pardini L, Kaeffer B, Trubuil A, Bourreille A, Galmiche JP. Human intestinal circadian clock: expression of clock genes in colonocytes lining the crypt. Chronobiol Int. 2005;22:951-961.
47. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318: 1108-1113.
48. Saha S, Bardelli A, Buckhaults P, et al. A phosphatase associated with metastasis of colorectal cancer. Science. 2001;294: 1343-1346.
49. Zhu K, Beiler J, Hunter S, et al. The relationship between menstrual factors and breast cancer according to estrogen receptor status of tumor: a case-control study in African- American women. Ethn Dis. 2002;12(4):S3-23-29
50. Zhu Y, Zheng T, Stevens RG, Zhang Y, Boyle P. Does "clock" matter in prostate cancer? Cancer Epidemiol Biomarkers Prev. 2006;15:3-5.
51. Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer. Cancer Res. 2007;67:10618-10622.
52. Zhu Y, Leaderer D, Guss C, et al. Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer. 2007;120:432-435.
53. Kubo T, Ozasa K, Mikami K, et al. Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. Am J Epidemiol. 2006;164:549-555.
54. Mormont MC, Levi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer. 2003;97:155-169.
55. Filipski E, King VM, Li X, et al. Disruption of circadian coordination accelerates malignant growth in mice. Pathol Biol (Paris). 2003;51:216-219.
56. Mormont MC, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000;6:3038-3045.
57. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92:994-1000.
58. Silberfarb PM, Hauri PJ, Oxman TE, Schnurr P. Assessment of sleep in patients with lung cancer and breast cancer. J Clin Oncol. 1993;11:997-1004.
59. Mormont MC, Waterhouse J. Contribution of the rest-activity circadian rhythm to quality of life in cancer patients. Chronobiol Int. 2002;19:313-323.
60. Sephton S, Spiegel D. Circadian disruption in cancer: a neuroendocrine- immune pathway from stress to disease? Brain Behav Immun. 2003;17:321-328.
61. Sheely LC. Sleep disturbances in hospitalized patients with cancer. Oncol Nurs Forum. 1996;23:109-111.
62. Evans TL. Highlights from the Tenth World Conference on Lung Cancer. Oncologist. 2004;9:232-238.
63. Haimov I, Lavie P. Melatonin: a chronobiotic and soporific hormone. Arch Gerontol Geriatr. 1997;24:167-173.
64. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. Science. 1980;210:1267-1269.
65. Danforth DN Jr, Tamarkin L, Mulvihill JJ, Bagley CS, Lippman ME. Plasma melatonin and the hormone-dependency of human breast cancer. J Clin Oncol. 1985;3:941-948.
66. Bartsch C, Bartsch H, Schmidt A, Ilg S, Bichler KH, Flüchter SH. Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta. 1992;209:153-167.
67. Lewy A, Cutler NL, Sack RL. The endogenous melatonin profile as a marker for circadian phase position. J Biol Rhythms. 1999;14:227-236.
68. Lissoni P, Barni S, Ardizzoia A, et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology. 1992;49:336-339.
69. Lissoni P, Barni S, Cazzaniga M, et al. Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone. Oncology. 1994;51:344-347.
70. Lissoni P, Rovelli F, Meregalli S, et al. Melatonin as a new possible anti-inflammatory agent. J Biol Regul Homeost Agents. 1997;11:157-159.
71. Lissoni P. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms. Ann N Y Acad Sci. 2000;917:560-567.
72. Levin RD, Daehler MA, Grutsch JF, et al. Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer. 2005;93:1202-1208.
73. Carpenter JS, Andrykowski MA. Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res. 1998;45:5-13.
74. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol. 2005;23:175-183.
75. Hrushesky WJM, Haus E, Lakatua D, Langevin T, Halberg F, Kennedy B. Marker rhythms for cancer chrono-chemotherapy. In: Haus E, Cabet H, eds. Chronobiology 1981-1983. New York, NY: Karger; 1985:493-499.
76. Karnofsky DA, Abelmann WH, Craver LF, Burchena L. The use of nitrogen mustards in the palliative treatment of cancer. Cancer. 1948;1:634-656.
77. Owen DC, Parker KP, McGuire DB. Comparison of subjective sleep quality in patients with cancer and healthy subjects. Oncol Nurs Forum. 1999;26:1649-1651.